Abstract: Slide Presentations |

RSV Prevention: Preliminary Demographic & Risk Factor Data For 918 Full Term Children (> 35 Wks Gestation) During The 2003-2004 RSV Season FREE TO VIEW

Wm. Brendle Glomb, MD; Marnie L. Boron, PharmD; Alan H. Cohen, MD; Niki L. Oquist, MD; Molly Rankin, MS; Bennie McWilliams, MD*
Author and Funding Information

Specially for Children, Austin, TX


Chest. 2004;126(4_MeetingAbstracts):777S-b-778S. doi:10.1378/chest.126.4_MeetingAbstracts.777S-b
Text Size: A A A
Published online


PURPOSE:  AAP Redbook guidelines for RSV prophylaxis include children < 2 yrs of age with chronic lung disease (CLD) and those with congenital heart disease (CHD). Since 2000, the Outcomes Registry has evaluated clinical practice among ∼20,000 children receiving RSV prophylaxis. This analysis was performed to characterize how RSV prevention is being clinically applied to at risk term children.

METHODS:  6087 children from 175 sites across the US who received at least one dose of palivizumab after June 1, 2003 were enrolled in the 2003-2004 Registry. Demographics, risk factors for RSV, injection history, and confirmed RSV-hospitalizations were recorded. Data for term children are presented.

RESULTS:  Fifteen percent (n=918) of the enrollees were >35 wks GA, up from 8% in 2000. Seventy percent of term children were Caucasian compared with 54% of those < 35 wks GA (p<0.001). Almost 60% of term infants reported either CHD (41%) or CLD (18%), compared to 21% with CHD in 2002-03. Risk factors for RSV included CF (3%), daycare (55%) or tobacco smoke exposure (19%), 3 2 people sharing a bedroom (47%), multiple birth (9%). Additionally, 45% had Medicaid compared to 49% of premature infants (p=0.0231). Term children were surveyed for the primary diagnostic reason for RSV prophylaxis: CHD (37%), CLD other than due to prematurity (16%), CF (3%), airway abnormality (4%), pulmonary hypoplasia/diaphragmatic hernia (2%), and other (38%).

CONCLUSION:  Clinical practice reporting in the Registry shows increasing use of palivizumab in term children, many who have important risk factors for RSV. Increasing use in children with CHD is likely related to changes in guidelines and recent study results.

CLINICAL IMPLICATIONS:  Physicians are increasingly identifying term children in whom RSV prevention appears appropriate, predominantly those with CHD and CLD.

DISCLOSURE:  B. McWilliams, MedImmune, Inc

Wednesday, October 27, 2004

10:30 AM- 12:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543